Allogene Therapeutics (ALLO) insider holdings: Dr. Chang 4.9% ownership disclosed

Rhea-AI Filing Summary

Allogene Therapeutics ownership update: David D. Chang and affiliated trusts report beneficial ownership of 12,297,354 shares of common stock, representing 4.9% of the class. The filing states 243,777,920 shares outstanding as of March 10, 2026.

The cover-page detail shows 6,345,007 shares exercisable within 60 days of March 31, 2026 (stock options held by Dr. Chang). Trust holdings listed include Chang 2006 Family Trust 1,201,108 shares, JEC 2019 Trust 856,044 shares, and RTC 2019 Trust 856,044 shares.

Key Figures

Aggregate beneficial ownership: 12,297,354 shares Percent of class: 4.9% Shares outstanding: 243,777,920 shares +4 more

7 metrics

Aggregate beneficial ownership 12,297,354 shares aggregate reported on cover pages

Percent of class 4.9% based on 243,777,920 shares outstanding as of March 10, 2026

Shares outstanding 243,777,920 shares as of March 10, 2026 from issuer 10-K

Options exercisable within 60 days 6,345,007 shares exercisable by Dr. Chang within 60 days of March 31, 2026

Chang 2006 Family Trust holdings 1,201,108 shares reported beneficial ownership by Chang 2006 Family Trust

JEC 2019 Trust holdings 856,044 shares reported beneficial ownership by JEC 2019 Trust

RTC 2019 Trust holdings 856,044 shares reported beneficial ownership by RTC 2019 Trust

Key Terms

Schedule 13G/A, beneficially owned, sole/shared dispositive power, exercisable within 60 days

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) Allogene Therapeutics, Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: Row 9 of each Reporting Person's cover page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole/shared dispositive power financial

"Sole Dispositive Power 9,384,158.00 8 | Shared Dispositive Power 2,913,196.00"

exercisable within 60 days regulatory

"6,345,007 shares of common stock issuable within 60 days of March 31, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:55 PM Learn about SEC filing dates

FAQ

What stake does David D. Chang hold in Allogene (ALLO)?

Dr. Chang and affiliated trusts beneficially own 12,297,354 shares, equal to 4.9% of the class. This position is calculated using 243,777,920 shares outstanding as of March 10, 2026, per the filing referenced in the schedule.

How many shares can Dr. Chang acquire soon for ALLO?

Dr. Chang has 6,345,007 shares exercisable within 60 days of March 31, 2026. The filing incorporates this exercisable option count into the aggregate beneficial ownership reported on the cover page.

What holdings do the affiliated trusts report in the 13G/A for ALLO?

The filing lists Chang 2006 Family Trust with 1,201,108 shares, JEC 2019 Trust with 856,044 shares, and RTC 2019 Trust with 856,044 shares. Each trust is shown with shared or sole dispositive/voting powers as detailed on the cover pages.

On what share base was the ownership percentage for ALLO calculated?

The 4.9% figure is calculated using 243,777,920 shares outstanding as of March 10, 2026. That outstanding share count is cited from the issuer's Quarterly Report on Form 10-K filed March 12, 2026 and incorporated by reference.

Does the 13G/A indicate any change in voting or dispositive power for ALLO shares?

The filing itemizes sole and shared voting and dispositive powers for Dr. Chang and each trust (e.g., Dr. Chang: sole voting power 9,384,158; shared voting power 2,913,196). It presents these holdings rather than announcing a transaction or transfer.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

019770106

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

David D. Chang, M.D., Ph.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,384,158.00
6	Shared Voting Power 2,913,196.00
7	Sole Dispositive Power 9,384,158.00
8	Shared Dispositive Power 2,913,196.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,297,354.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Chang 2006 Family Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,201,108.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,201,108.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,201,108.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

JEC 2019 Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 856,044.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 856,044.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

856,044.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

RTC 2019 Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 856,044.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 856,044.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

856,044.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Allogene Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 210 East Grand Avenue, South San Francisco, CA, 94080.
Item 2.
(a)	Name of person filing: David D. Chang, M.D., Ph.D. Chang 2006 Family Trust JEC 2019 Trust RTC 2019 Trust
(b)	Address or principal business office or, if none, residence: David D. Chang, M.D., Ph.D.: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 Chang 2006 Family Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 JEC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 RTC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401
(c)	Citizenship: David D. Chang, M.D. Ph.D.: USA Chang 2006 Family Trust: California JEC 2019 Trust: California RTC 2019 Trust: California
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 019770106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Chang's cover page includes 6,345,007 shares of common stock issuable within 60 days of March 31, 2026 upon the exercise of stock options held by Dr. Chang, and also includes (a) 1,201,108 shares of common stock beneficially owned by the Chang 2006 Family Trust, of which Dr. Chang is co-trustee, (b) 856,044 shares of common stock beneficially owned by the JEC 2019 Trust, of which Dr. Chang is co-trustee and (c) 856,044 shares of common stock beneficially owned by the RTC 2019 Trust, of which Dr. Chang is co-trustee.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 243,777,920 shares of common stock outstanding as of March 10, 2026, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 12, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

David D. Chang, M.D., Ph.D.

Signature:	/s/ David D. Chang
Name/Title:	David D. Chang, M.D., Ph.D.
Date:	05/13/2026

Chang 2006 Family Trust

Signature:	/s/ David D. Chang
Name/Title:	By David D. Chang, M.D., Ph.D., Co-Trustee
Date:	05/13/2026

JEC 2019 Trust

Signature:	/s/ David D. Chang
Name/Title:	By David D. Chang, M.D., Ph.D., Co-Trustee
Date:	05/13/2026

RTC 2019 Trust

Signature:	/s/ David D. Chang
Name/Title:	By David D. Chang, M.D., Ph.D., Co-Trustee
Date:	05/13/2026

Exhibit Information

Joint Filing Agreement